J. Kirk

G. Giles, J. Hopper, M. Southey, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A decision aid for women at increased risk for ovarian cancer

L. Andrews, J. Kirk, M. Friedlander, 2002, International Journal of Gynecologic Cancer.

Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics

L. Andrews, J. Kirk, K. Tucker, 2020, Familial Cancer.

A Randomized Controlled Trial of a Decision Aid for Women at Increased Risk of Ovarian Cancer

J. Kirk, M. Friedlander, B. Meiser, 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Alexander M. Metcalf, A. Spurdle, F. Lose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation analysis of the MYH gene in an Australian series of colorectal polyposis patients with or without germline APC mutations

R. Scott, A. Spigelman, J. Kirk, 2005, International journal of cancer.

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

David M. Thomas, I. Martincorena, M. Syed, 2020, Nature medicine.

The family history of cancer – a common concern in palliative care

J. Kirk, 2004 .

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Mads Thomassen, Nina Ditsch, Vijai Joseph, 2012, Breast Cancer Research.

Prostate Cancer Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA 2 Mutation Carriers

W. Foulkes, A. Ardern-Jones, E. Page, 2019 .

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

L. Kiemeney, L. Andrews, R. Eeles, 2019, European urology.

The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.

J. Kirk, M. Friedlander, N. Pachter, 2020, Gynecologic oncology.

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.

G. Mann, P. Butow, J. Kirk, 2018, Contemporary clinical trials.

New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer

A. deFazio, J. Kirk, K. Tucker, 2015, Journal of Cancer Education.

What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.

J. Kirk, S. Domchek, M. Hickey, 2021, Gynecologic oncology.

Knowledge, attitudes and beliefs of Arabic‐Australians concerning cancer

J. Kirk, B. Meiser, K. Barlow-Stewart, 2012, Psycho-oncology.

Women’s preferences and consultants’ communication of risk in consultations about familial breast cancer: impact on patient outcomes

P. Butow, J. Kirk, A. Barratt, 2003, Journal of medical genetics.

trialhigh risk breast cancer families: a randomised The use of audiotapes in consultations with women

P. Butow, J. Kirk, A. Barratt, 2008 .

The use of audiotapes in consultations with women from high risk breast cancer families: a randomised trial

P. Butow, J. Kirk, A. Barratt, 2002, Journal of medical genetics.

Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling?

J. Kirk, B. Meiser, K. Barlow-Stewart, 2011, Genetics in Medicine.

Qualitatively understanding patients' and health professionals' experiences of the BRECONDA breast reconstruction decision aid

L. Cameron, J. Kirk, K. Tucker, 2017, Psycho-oncology.

Cancer in the family: risks and management

J. Kirk, Richard Keffordm, 2000, The Medical journal of Australia.

A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy

J. Kirk, S. Domchek, M. Hickey, 2021, Menopause.

Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.

J. Kirk, B. Meiser, K. Barlow-Stewart, 2013, Personalized medicine.

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

W. Chung, R. Nussbaum, F. Couch, 2016, Breast Cancer Research and Treatment.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012, Breast Cancer Research.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry

Annette Lee, F. Couch, O. Olopade, 2019, Human mutation.

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation

J. Kirk, G. Lindeman, Y. Antill, 2005, Breast Cancer Research.

Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2).

J. Kirk, N. Kasparian, C. Wakefield, 2008, Genetic testing.

A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history.

J. Hopper, J. Kirk, J. Hopper, 2003, Breast.

Association of hereditary angioedema and hereditary breast cancer.

C. Clarke, J. Kirk, J. Boyages, 1997, Cancer genetics and cytogenetics.

Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial

J. Kirk, B. Meiser, K. Barlow-Stewart, 2016, Genetics in Medicine.

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.

F. Couch, P. Møller, J. Hopper, 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

University of Southern Denmark Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

L. Kiemeney, L. Andrews, R. Eeles, 2018 .

What’s in a Name? Parents’ and Healthcare Professionals’ Preferred Terminology for Pathogenic Variants in Childhood Cancer Predisposition Genes

Jonathan M Marron, Katherine M. Tucker, J. Kirk, 2022, Journal of personalized medicine.

Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study

J. Kirk, A. Smit, Sharne Limb, 2022, Journal of personalized medicine.

Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer

J. Kirk, B. Meiser, K. Barlow-Stewart, 2014, Familial Cancer.

Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility

L. Andrews, A. Spurdle, J. Kirk, 2020, Journal of Medical Genetics.

Attitudes toward genetic testing for cancer risk after genetic counseling and decision support: a qualitative comparison between hereditary cancer types.

J. Kirk, J. Homewood, B. Meiser, 2007, Genetic testing.

Reply to J. Moline et al.

Alexander M. Metcalf, A. Spurdle, F. Lose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics

Mark C. Field, L. Andrews, J. Kirk, 2020, Familial Cancer.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Neil L. Aaronson, L. Kiemeney, L. Andrews, 2018, British Journal of Cancer.

The NSW & ACT Hereditary Cancer Registers.

R. Scott, A. Spigelman, J. Kirk, 2005, Australian family physician.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

David R. Croucher, J. Kench, L. Andrews, 2019, Nature Communications.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

D. Steinemann, F. Couch, B. Bonanni, 2016, PloS one.

Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing

A. Spurdle, J. Kirk, J. Shamsani, 2017, Modern Pathology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer

J. Kirk, F. Saletta, N. Graf, 2021, Genes, chromosomes & cancer.

Timing and context: important considerations in the return of genetic results to research participants

J. Kirk, N. Hallowell, M. Ballinger, 2015, Journal of Community Genetics.

Li-Fraumeni syndrome: cancer risk assessment and clinical management

David M. Thomas, R. Eeles, J. Kirk, 2014, Nature Reviews Clinical Oncology.

Inherited cancer susceptibility syndromes in paediatric practice

J. Kirk, S. Shanley, M. Field, 2007, Journal of paediatrics and child health.

Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families

M. Southey, G. Chenevix-Trench, I. Makunin, 2015, Journal of Medical Genetics.

Histopathological features of breast cancer in carriers of ATM gene variants

K. Byth, G. Farshid, R. Balleine, 2006, Histopathology.

Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?

M. Brown, M. Marshall, T. Dwight, 2020, The Journal of clinical endocrinology and metabolism.

Homologous recombination DNA repair defects in PALB2-associated breast cancers

I. Hickie, L. Lipton, A. Shelling, 2019, npj Breast Cancer.

Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

A. deFazio, P. Beale, R. Balleine, 2023, Translational oncology.

Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer.

P. Butow, J. Kirk, K. Tucker, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intention t o U ndergo P rophylactic B ilateral M astectomy in W omen a t I ncreased R isk o f D eveloping H ereditary Breast C ancer

P. Butow, J. Kirk, M. Friedlander, 2000 .

Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.

C. Clarke, J. Kirk, E. Jarvis, 1998, Cancer genetics and cytogenetics.

Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.

N. Hacker, J. Kirk, M. Quinn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine

R. Eeles, Z. Kote-Jarai, D. Neal, 2010, PloS one.

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

L. Kiemeney, R. Eeles, Z. Kote-Jarai, 2014, European urology.

Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development

J. Pearson, A. Spurdle, S. Lakhani, 2021, Cancers.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Elizabeth Lobb, Judi Homewood, Michelle Peate, 2007, Breast Cancer Research and Treatment.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource

John L Hopper, Edward Edkins, Phyllis N Butow, 2006, Breast Cancer Research.

The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group.

M. Beckmann, T. Sellers, M. Stratton, 2000, American journal of human genetics.

The role of familial cancer services

J. Kirk, 2007 .

Long-term outcomes of genetic counseling in women at increased risk of developing hereditary breast cancer.

P. Butow, J. Kirk, A. Barratt, 2001, Patient education and counseling.

Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds.

R. Scott, A. Spigelman, J. Kirk, 2001, American journal of human genetics.

Mainstream genetic testing for high‐grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience

J. Kirk, P. Harnett, A. Brand, 2023, The Australian & New Zealand journal of obstetrics & gynaecology.

Helping young children understand inherited cancer predisposition syndromes using bibliotherapy

J. Kirk, A. Crook, J. Fleming, 2021, Journal of genetic counseling.

Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families

J. Kirk, J. Leary, T. Davis, 2005, Journal of Medical Genetics.

Familial adenomatous polyposis: more evidence for disease diversity and genetic heterogeneity

R. Scott, J. Kirk, C. Meldrum, 2001, Gut.

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

I. Martincorena, M. Syed, J. Kirk, 2020, Nature Medicine.

Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression

R. Nussbaum, F. Couch, O. Olopade, 2016 .

Hereditary colorectal cancer. What you need to know

J. Kirk, K. Wu, 2015 .

Development of a Communication Aid to Facilitate Risk Communication in Consultations with Unaffected Women from High Risk Breast Cancer Families: A Pilot Study

P. Butow, J. Kirk, A. Barratt, 2006, Journal of Genetic Counseling.

MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer.

Megan Hitchins, Rodney Scott, Ian Tomlinson, 2005, Gastroenterology.

Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A

G. Chenevix-Trench, C. Clarke, J. Kirk, 2004, Genes, chromosomes & cancer.

Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers

Gillian Mitchell, J. Kirk, I. Campbell, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing

Daniel J. Park, Katherine M. Tucker, R. Sebra, 2021, npj Breast Cancer.

Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing

Daniel J. Park, R. Sebra, G. Giles, 2021, NPJ breast cancer.

Frequency of the ATM IVS10-6T→G variant in Australian multiple-case breast cancer families

J. Visvader, J. Kirk, G. Lindeman, 2004, Breast Cancer Research.

BREAST CANCER IN YOUNG WOMEN

J. Kirk, M. Brennan, J. French, 2004, International Journal of Gynecologic Cancer.

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

J. Kirk, P. Butow, K. Dunlop, 2017, The British journal of dermatology.

ROR1 and ROR2 expression in pancreatic cancer

J. Kench, L. Andrews, J. Pearson, 2021, BMC Cancer.

Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

R. Eeles, J. Kirk, S. Shanley, 2017, Familial Cancer.

Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer

P. Butow, J. Kirk, K. Tucker, 2001, Internal medicine journal.

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

GP attitudes to and expectations for providing personal genomic risk information to the public: a qualitative study

P. Butow, J. Kirk, L. Trevena, 2019, BJGP open.

The impact of coding germline variants on contralateral breast cancer risk and survival

W. He, A. Børresen-Dale, N. Camp, 2023, American journal of human genetics.

Breast cancer immunohistochemistry can be useful in triage of some HNPCC families

J. Kirk, S. Shanley, C. Fung, 2009, Familial Cancer.

Evaluation of models to predict BRCA germline mutations

J. Kirk, R. Ward, C. Ringland, 2006, British Journal of Cancer.

Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial

G. Mann, P. Butow, J. Kirk, 2021, Genetics in Medicine.

cancer phenotype in selected families are a feature of the inherited breast/ovarian BRCA1 and BRCA2 Large genomic rearrangements of both

J. Kirk, T. Davis, A. Woodward, 2005 .

Gene silencing.

J. Kirk, 2004, New England Journal of Medicine.

Whole body screening , TP 53 mutation carriers , psychosocial morbidity Psychosocial morbidity in TP 53 mutation carriers – is whole-body cancer screening beneficial ?

David M. Thomas, R. Eeles, J. Kirk, 2016 .

Tailoring communication in consultations with women from high risk breast cancer families

P. Butow, J. Kirk, A. Barratt, 2002, British Journal of Cancer.

Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.

P. Butow, J. Kirk, K. Tucker, 1999, Gynecologic oncology.

The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan

G. Mann, P. Butow, J. Kirk, 2020, Trials.

Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer

P. Butow, K. Aittomäki, J. Kirk, 2004, Breast Cancer Research and Treatment.

Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review

J. Kirk, B. Meiser, C. Julian‐Reynier, 2017, Hereditary Cancer in Clinical Practice.

Loss of MSH6 and PMS2 immunohistochemical staining in tumour tissue of two individuals with a germline PMS2 mutation

J. Kirk, M. Walsh, E. Edwards, 2012, Hereditary Cancer in Clinical Practice.

Exploring clinicians’ attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer

J. Kirk, R. Ward, B. Meiser, 2016, Familial Cancer.

Women’s Experience of Telehealth Cancer Genetic Counseling

J. Kirk, B. Meiser, E. Lobb, 2010, Journal of Genetic Counseling.

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Katherine M. Tucker, L. Kiemeney, H. Grönberg, 2011, BJU international.

Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.

A. Spurdle, J. Kirk, M. Quinn, 2017, Gynecologic oncology.

How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

J. Duffy, J. Kirk, M. Friedlander, 2012, BMC Cancer.

Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history

J. Kirk, B. Meiser, K. Barlow-Stewart, 2018, European Journal of Human Genetics.

New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer

A. deFazio, J. Kirk, K. Tucker, 2015, Journal of Cancer Education.

Assessing the medical workforces perceived barriers to the prescription of risk‐reducing medication for women at high‐risk of breast cancer

J. Kirk, B. Meiser, R. Kaur, 2019, The breast journal.

Development and Pilot Testing of Two Decision Aids for Individuals Considering Genetic Testing for Cancer Risk

Clara Gaff, Elizabeth Lobb, Judi Homewood, 2007, Journal of Genetic Counseling.

Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General Practice

J. Kirk, T. Dobbins, L. Trevena, 2022, Public Health Genomics.

A pilot randomised controlled trial of the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public

G. Mann, P. Butow, J. Kirk, 2016 .

Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers

M. Jenkins, J. Kirk, A. Dobrovic, 2023, Clinical Epigenetics.

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

R. Eeles, Z. Kote-Jarai, E. Page, 2013, Scientific Reports.

What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.

J. Kirk, S. Domchek, M. Hickey, 2021, Gynecologic oncology.

Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer.

J. Kirk, M. Young, Y. Antill, 2006, European journal of cancer.

Getting to the point : What women newly diagnosed with breast cancer want to know about treatment-focused genetic testing

J. Kirk, B. Meiser, K. Barlow-Stewart, 2015 .

Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review

J. Kirk, B. Meiser, C. Julian‐Reynier, 2017, Hereditary cancer in clinical practice.

Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma

P. Butow, J. Kirk, M. Best, 2018, European Journal of Human Genetics.

Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study

J. Kirk, M. Pinese, L. Lau, 2023, BMJ Open.

When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer

J. Kirk, B. Meiser, K. Barlow-Stewart, 2016, European Journal of Human Genetics.

Development and Evaluation of a Telephone Communication Protocol for the Delivery of Personalized Melanoma Genomic Risk to the General Population

P. Butow, J. Kirk, K. Dunlop, 2018, Journal of Genetic Counseling.

Timing and context: important considerations in the return of genetic results to research participants

David M. Thomas, J. Kirk, M. Tattersall, 2015, Journal of Community Genetics.

kConFab: a research resource of Australasian breast cancer families

R. Osborne, G. Chenevix-Trench, J. Kirk, 2000, The Medical journal of Australia.

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Jane E. Carpenter, Jack A. Taylor, S. Cross, 2022, Breast Cancer Research.

Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.

Katherine M. Tucker, J. Kirk, M. Cowley, 2023, Cancer.

Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing.

J. Kirk, B. Meiser, K. Barlow-Stewart, 2012, Oncology nursing forum.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Mithat Gönen, Katherine M. Tucker, Jedd D. Wolchok, 2017, Nature.

Genome-wide association study identifies novel breast cancer susceptibility loci

Lester L. Peters, A. Uitterlinden, D. Cox, 2007, Nature.

A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public

G. Mann, P. Butow, J. Kirk, 2016, Cancer Epidemiology, Biomarkers & Prevention.

A pilot randomised controlled trial of the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public

G. Mann, P. Butow, J. Kirk, 2016 .

A multidisciplinary risk management clinic for women at high genetic risk of breast and ovarian cancer—Experience and evaluation

M. E. Brennan, J. Kirk, A. Brand, 2008 .

Medicare‐funded cancer genetic tests: a note of caution

J. Kirk, M. Friedlander, K. Barlow-Stewart, 2018, Medical Journal of Australia.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Common variants at 12 p 11 , 12 q 24 , 9 p 21 , 9 q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, David Evans, 2017 .

Homologous recombination DNA repair defects in PALB2-associated breast cancers

I. Hickie, L. Lipton, A. Shelling, 2019, npj Breast Cancer.

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer

Jordan F Hastings, David R. Croucher, J. Kench, 2023, Nature Cancer.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.

A. Spurdle, J. Kirk, M. Quinn, 2017, Gynecologic oncology.

A pilot randomised controlled trial of the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public

G. Mann, P. Butow, J. Kirk, 2016 .

Patient perspectives on molecular tumor profiling: “Why wouldn’t you?”

P. Butow, J. Kirk, M. Best, 2019, BMC Cancer.

GP attitudes to and expectations for providing personal genomic risk information to the public: a qualitative study

P. Butow, J. Kirk, L. Trevena, 2019, BJGP open.

Attitudes toward genetic testing for cancer risk after genetic counseling and decision support: a qualitative comparison between hereditary cancer types.

J. Kirk, J. Homewood, B. Meiser, 2007, Genetic testing.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

L. Kiemeney, L. Andrews, R. Eeles, 2018, British Journal of Cancer.

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.

F. Couch, P. Møller, J. Hopper, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma

P. Butow, J. Kirk, M. Best, 2018, European Journal of Human Genetics.

Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history

J. Kirk, B. Meiser, K. Barlow-Stewart, 2018, European Journal of Human Genetics.

Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.

J. Kirk, B. Meiser, K. Barlow-Stewart, 2013, Personalized medicine.

Gene silencing.

J. Kirk, 2004, New England Journal of Medicine.